Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
1745studies shown
Showing 1,645-1,656 of 1,745
Drug study icon
TerminatedNCT01677182

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolarity type I

This study exists to explore whether the medication Ramelteon could improve care and understanding. Researchers are trying to understand whether the medication Ramelteon can give earlier or clearer feedback during care.

In United Kingdom
BipolarityDrugA study involving a medication or substance.From 18 Years to 75 Years
Countries
United States, United Kingdom, Bulgaria, ...
Sponsor
Takeda
Condition
Bipolarity
Drug study icon
CompletedNCT01922258

Flexible Dosing of Brexpiprazole for Mental health

This study is completed in the United States, in France, in Canada, .... It is testing flexible Dosing of Brexpiprazole for Mental health.

In United Kingdom
Mental healthDrugFrom 55 Years to 90 Years
Countries
United States, France, Canada, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Mental health
Drug study icon
CompletedNCT04158453

Safety, Blood Levels and Effects of AUT00201

This summary needs review. Please check the official study record and contact the research team for details.

In United Kingdom
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United Kingdom
Sponsor
Autifony Therapeutics Limited
Condition
Schizophrenia
Drug study icon
CompletedNCT02589262

Safety, Blood Levels and Effects of AUT00206

This summary needs review. Please check the official study record and contact the research team for details.

In United Kingdom
SchizophreniaDrugFrom 18 Years to 45 Years
Countries
United Kingdom
Sponsor
Autifony Therapeutics Limited
Condition
Schizophrenia
Drug study icon
CompletedNCT03164876

Safety study of AUT00206 in schizophrenia

This study is completed in the United Kingdom. It is testing AUT00206 for schizophrenia.

In United Kingdom
SchizophreniaDrugFrom 18 Years to 50 Years
Countries
United Kingdom
Sponsor
Autifony Therapeutics Limited
Condition
Schizophrenia
Drug study icon
CompletedNCT00743405

Safety study of GSK1034702 in Schizophrenia

This study is completed in the United Kingdom. It is testing GSK1034702 for Schizophrenia.

In United Kingdom
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United Kingdom
Sponsor
GlaxoSmithKline
Condition
Schizophrenia
Behavioral study icon
CompletedNCT06451965

SCED - Wisdom Enhancement for Post-Stroke Depression

This summary needs review. Please check the official study record and contact the research team for details.

In United Kingdom
DepressionBehavioralOver 18 Years
Countries
United Kingdom
Sponsor
University of East Anglia
Condition
Depression
Drug study icon
CompletedNCT00237913

Schizophrenia study of Aripiprazole

This summary needs review. Please check the official study record and contact the research team for details.

In United Kingdom
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
France, United Kingdom, Austria, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.